Molbio Diagnostics & ShanMukha to offer rapid, low-cost portable devices for detection of blood disorders
This collaboration builds on the strengths of the two companies to drive cutting-edge technology
Stay updated with breaking news from Molbio Diagnostics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This collaboration builds on the strengths of the two companies to drive cutting-edge technology
In 2021, TB killed an estimated 1.6 million people with most deaths occurring in low and middle-income countries.
The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), the United States Agency for International Development (USAID) and the Stop TB Partnership announced a new collaboration Thursday with Molbio Diagnostics that significantly reduces the price of the Truenat® MTB and MTB Plus tests, including a supply of MTB-RIF Dx tests for subsequent testing for rifampicin resistance, and ensures timely service and maintenance of diagnostic instruments.
The aim is to reduce turnaround time for testing, reduce errors, and help in early diagnosis and initiation of correct treatment
The aim is to reduce turnaround time for testing, reduce errors, and help in early diagnosis and initiation of correct treatment